Abstract: A nanocomposite, comprising single-wall and/or multi-wall one-dimensional nanomaterials, and at least one nanooxide of at least one transition metal, said nanooxide filling said nanotubes and covering their walls. A process for preparing such a nanocomposite and an optical limiting device comprising such a nanocomposite in suspension in a medium that is transparent to visible and infrared radiation are disclosed.

Abstract: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell proliferation and in particular cancer.

Abstract: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell proliferation and in particular cancer.

Abstract: In the field of devices employing stimulated emission, a long-range laser illuminator may include a matrix of high-brightness infrared emitters. Each emitter is able to emit a first beam. The illuminator may be able to process the first beams coming from emitters disposed opposite and in the vicinity of the matrix. The illuminator may also be able to assemble the beams into a second unique, homogenous beam. The illuminator may include a prism including a planar input face disposed opposite the emitter matrix and a planar output face, the latter being disposed opposite a collimation lens.

Abstract: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell proliferation and in particular cancer.

Abstract: The present invention concerns a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are TIF2 antibodies. Screening methods are also provided for identifying agonists and antagonists of the activation function AF-2 of nuclear receptors, for identifying agonists and antagonists of the AD1 activation domain activity of TIF2, and for identifying agonists and antagonists of the AD2 activation domain activity of TIF2.

Abstract: The present invention relates in particular to the field of devices using stimulated emission, specifically to a device for collimating high-brightness laser diode array (1) characterized in that by comprising at least one optical fiber (2) whose first end (7) is thermoformed and is located in the vicinity of an opposite the high-brightness array (1), the numerical aperture of said optical fiber end being greater than the numerical aperture of the source.

Abstract: The present invention concerns a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are TIF2 antibodies. Screening methods are also provided for identifying agonists and antagonists of the activation finction AF-2 of nuclear receptors, for identifying agonists and antagonists of the AD1 activation domain activity of TIF2, and for identifying agonists and antagonists of the AD2 activation domain activity of TIF2.

Abstract: The present invention discloses methods for preparing antibodies which bind to specific isoforms of the human retinoic acid receptor-.gamma. (RAR-.gamma.). In addition, several monoclonal antibodies are described which bind to human RAR-.gamma., but not to mouse or which bind to RAR-.gamma.1, but not to RAR-.gamma.2. Methods and kits are described which allow one to detect the isotype of RAR-.gamma. which is expressed in a test sample. Such methods are useful in determining the tissue specific pattern of expression of various RAR-.gamma. isoforms.